Pharmaceuticals

Tremfya Market 2026 expanding with increased adoption of biologics for autoimmune diseases

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Tremfya Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

Historical growth is linked to a growing incidence of psoriasis and psoriatic arthritis, the proven effectiveness of biologic treatments, the broader availability of specialized dermatology services, enhanced patient compliance with biologic medications, and more extensive insurance coverage for biologic pharmaceuticals.

The observed growth during the forecast period is due to a rising need for the long-term management of inflammatory diseases, the broadening application of biologics in gastroenterology, an increasing preference for less frequent dosing schedules, expanding investments in monoclonal antibody therapies, and a heightened emphasis on personalized immunology treatments.

Significant trends expected in the forecast period involve the growing acceptance of IL-23 inhibitor therapies, an increasing call for biologic treatments with extended intervals, the expansion of indications for autoimmune diseases, a rise in the use of subcutaneous biologic injections, and a more pronounced focus on targeted immunomodulation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Tremfya Market?

The increasing prevalence of autoimmune diseases is set to drive the expansion of the tremfya market moving forward. Autoimmune diseases are characterized by the body’s immune system mistakenly attacking its own cells, tissues, or organs, perceiving them as foreign invaders. The rising occurrence of these conditions stems from genetic predisposition, environmental triggers, changes in lifestyle, greater awareness, and improved diagnostic capabilities. Tremfya, a monoclonal antibody targeting interleukin-23 (IL-23), contributes to managing autoimmune diseases by modulating the immune system’s overactive response, reducing inflammation, and alleviating symptoms in conditions such as psoriasis and psoriatic arthritis. For instance, data from February 2024 provided by Arthritis Australia, an Australia-based non-profit organization, indicates that in 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Thus, the escalating prevalence of autoimmune diseases is fostering the growth of the tremfya market.

What Major Segment Divisions Exist Within The Tremfya Market?

The tremfya market covered in this report is segmented –

1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA

2) By Formulation: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

4) By End User: Adult Patients, Geriatric Patients

How Are Trends Shaping The Direction Of The Tremfya Market?

Leading companies in the Tremfya market are securing regulatory clearances to extend its approved uses, including for moderate-to-severe Crohn’s disease, thereby expanding its patient population and market reach. These regulatory authorizations are formal permissions issued by bodies like the Food and Drug Administration (FDA) or the European Medicines Agency (EMA), enabling a medication to be sold for particular purposes once its safety, effectiveness, and quality have been proven. An example is Johnson & Johnson, a US-based pharmaceutical firm, which obtained FDA approval in September 2024 for TREMFYA (guselkumab) to treat adults experiencing moderately to severely active ulcerative colitis; this established it as the initial dual-acting interleukin-23 inhibitor cleared for this specific ailment. This decision stemmed from favorable outcomes of the Phase 2b/3 QUASAR study, where roughly 50% of participants achieved clinical remission following 44 weeks of therapy. TREMFYA works by targeting interleukin-23, which aids in normalizing the inflammatory processes within the colon.

Which Companies Are Leading Innovation In The Tremfya Market?

Major companies operating in the tremfya market are Johnson & Johnson

Read the full tremfya market report here:

https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report

What Are The Leading Geographic Regions In The Tremfya Market?

North America was the largest region in the tremfy market in 2025. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tremfya Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20343&type=smp

Browse Through More Reports Similar to the Global Tremfya Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795